Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Conflict of interest statement br Dr

    2020-08-14


    Conflict of interest statement
    Dr. Matei reports personal fees from Astra Zeneca, Genentech/Roche, Tesaro, Astex, Clovis, and the European commission that Influenza Hemagglutinin HA Peptide are outside the submitted work. All other authors report no conflicts of interest.
    Author contributions
    Conceptualization: Goodman, Seagle, Strauss. Formal Analysis and
    Methodology: Goodman, Strauss, Hatoum, Seagle. Writing – Original
    Draft: Goodman, Hatoum; Writing – Review and Editing: Goodman,
    Hatoum, Seagle, Barber, Matei, Strauss. Project Administration: Hatoum,
    Donnelly, Barber, Matei, Shahabi, Strauss. Supervision: Strauss, Shahabi.
    References
    [1] S.M. de Boer, M.E. Powell, L. Mileshkin, et al., Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial, Lancet Oncol. 19 (3) (2018) 295–309. [2] D. Matei, V.L. Filiaci, M. Randall, et al., A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma, J. Clin. Oncol. 35 (15_suppl) (2017) 5505. [3] K.Y. Bilimoria, A.K. Stewart, D.P. Winchester, C.Y. Ko, The National Cancer Data Base: a powerful initiative to improve cancer care in the United States, Ann. Surg. Oncol. 15 (3) (2008) 683–690.
    [13] MatchIt, Nonparametric Preprocessing for Parametric Causal Inference, computer program 2011. [14] T.M. Therneau, A Package for Survival Analysis in S. Version 2.38, https://CRAN.R-project.org/package=survival 2015. [15] Team RC (Ed.), R: A Language and Environment for Statistical Computing, R Foun-dation for Statistical Computing, Vienna, Austria, 2016. [16] R. Maggi, A. Lissoni, F. Spina, et al., Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial, Br. J. Cancer 95 (3) (2006) 266–271.
    [17] N. Susumu, S. Sagae, Y. Udagawa, et al., Randomized phase III trial of pelvic radio-therapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study, Gynecol. Oncol. 108 (1) (2008) 226–233.
    [18] M.E. Randall, V.L. Filiaci, H. Muss, et al., Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study, J. Clin. Oncol. 24 (1) (2006) 36–44.
    [19] H. Gao, Z. Zhang, Sequential chemotherapy and radiotherapy in the sandwich method for advanced endometrial cancer: a meta-analysis, Medicine (Baltimore) 94 (16) (2015) e672.
    [20] M. Glasgow, R.I. Vogel, J. Burgart, P. Argenta, K. Dusenbery, M.A. Geller, Long term follow-up of a phase II trial of multimodal therapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer, Gynecol. Oncol. Res. Pract. 3 (2016) 6.
    [23] M.H. Einstein, M. Frimer, D.Y. Kuo, et al., Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma, Gynecol. Oncol. 124 (1) (2012) 21–25.
    www.neoplasia.com
    Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer
    * Center for Colorectal Cancer, National Cancer Center, Goyang, Korea; †Precision Medicine Branch, Division of Precision Medicine, Research Institute of National Cancer Center, Goyang, Korea; ‡Translational Research Branch, Division of Translational Science, Research Institute of National Cancer Center, Goyang, Korea; §Molecular Epidemiology Branch, Division of Cancer Epidemiology and Prevention, Research Institute of National Cancer Center, Goyang, Korea
    Abstract
    Aberrant promoter methylation plays a vital role in colorectal carcinogenesis. However, its role in treatment responses is unclear, especially for metastatic disease. Here, we investigated the association between promoter methylation and treatment outcomes of irinotecan-based chemotherapy in 102 patients with metastatic colorectal cancer. Promoter methylation was examined by methylation-specific polymerase chain reaction for three loci (CHFR, WRN, and SULF2) associated with chemotherapy response and five CpG island methylator phenotype (CIMP)–specific markers (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1). Association between CHFR methylation and in vitro sensitivity to irinotecan was also evaluated. Promoter methylation of CHFR, WRN, and SULF2 was identified in 16 (15.7%), 24 (23.5%), and 33 (32.4%)
    patients, respectively. CIMP status was positive in 22 (21.6%) patients. CHFR methylation was associated with a significantly longer time to progression (TTP) (median: 8.77 vs. 4.43 months, P = .019), with trends favoring higher overall survival (OS) (median: 22.83 vs. 20.17 months, P = .300) and response rates (31.3% vs. 17.4%, P = .300). For patients with unmethylated CHFR, TTP (median: 5.60 vs. 3.53, P = .020) and OS (median: 20.57 vs. 9.23, P = .006) were significantly different according to CIMP status. Colorectal cancer cell lines with CHFR methylation demonstrated increased sensitivity to irinotecan. Both CHFR overexpression and combination with 5-aza-2′-deoxycytidine reversed irinotecan sensitivity in CHFR-methylated cell lines, whereas CHFR knockdown in unmethylated cells restored sensitivity to irinotecan. These data suggest that CHFR methylation may be associated with favorable treatment outcomes of irinotecan-based chemotherapy in patients with metastatic colorectal cancer.